A CFTR Potentiator in Patients with Cystic Fibrosis and the <i>G551D</i> Mutation

Bonnie W. Ramsey, Jane C. Davies, Noel G. McElvaney, +16

New England Journal of Medicine

Efficacy and Safety of Ivacaftor in Patients Aged 6 to 11 Years with Cystic Fibrosis with a <i>G551D</i> Mutation

Jane C. Davies, Claire Wainwright, Gerard J. Canny, +9

American Journal of Respiratory and Critical Care Medicine

Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the <i>F508del-CFTR</i> mutation

John P. Clancy, Steven M. Rowe, Frank J. Accurso, +27

Thorax

Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies

Nicola A. Hanania, Michael Noonan, Jonathan Corren, +15

Thorax

Ivacaftor in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation

Patrick A. Flume, Theodore G. Liou, Drucy Borowitz, +4

CHEST Journal

FibrosisMendelian DisorderGenetic DisorderGeneticsPathogenesis +7

Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE)

Eric L. Simpson, Carsten Flohr, Lawrence F. Eichenfield, +10

Journal of the American Academy of Dermatology

Stride Velocity 95th Centile: Insights into Gaining Regulatory Qualification of the First Wearable-Derived Digital Endpoint for use in Duchenne Muscular Dystrophy Trials

Laurent Servais, Karl Yen, Maitea Guridi, +3

Journal of Neuromuscular Diseases

Gait AnalysisPhysical ActivityNeuromuscular CoordinationWearable TechnologyOrthopaedic Surgery +21

Efficacy and safety of lebrikizumab in adult patients with mild-to-moderate asthma not receiving inhaled corticosteroids

Philip Korenblat, Edwin Kerwin, Karl Yen, +7

Respiratory Medicine

Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis

Stephan Weidinger, Andrew Blauvelt, Kim Papp, +17

Journal of Allergy and Clinical Immunology

Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation

Inez Bronsveld, Karl Yen

UNC Libraries